Arcutis Biotherapeutics/ARQT

$10.99

13.41%
-
1D1W1MYTD1YMAX

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an established biological target in dermatology. It is also developing roflumilast cream for the treatment of atopic dermatitis. ZORYVE is designed for simple once-a-day application for chronic use, does not burn or sting on application, and can be used on any part of the body, including sensitive or difficult-to-treat areas, such as the face and intertriginous regions.

Ticker

ARQT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Watanabe

Employees

268

Headquarters

Westlake village, United States

ARQT Metrics

BasicAdvanced
$913.62M
Market cap
-
P/E ratio
-$4.37
EPS
1.12
Beta
-
Dividend rate

What the Analysts think about ARQT

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
9.19% upside
High $20.00
Low $6.00
$10.99
Current price
$12.00
Average price target

ARQT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-117.32% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$38.1M
647.06%
Net income
$-44.7M
-36.95%
Profit margin
-117.32%
-91.56%

ARQT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.87%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.18
-$1.31
-$1.16
-$0.73
-
Expected
-$1.42
-$1.28
-$1.25
-$0.86
-$0.78
Surprise
-17.08%
1.97%
-7.21%
-14.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Arcutis Biotherapeutics stock

Buy or sell Arcutis Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing